Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?

Marzio E E Sabbioni, Jürg Bernhard, Hans Peter Siegrist, Shu Fang Hsu Schmitz, Monica Castiglione Gertsch, Beat Thürlimann, Hervé Bonnefoi, Lucien Perey, Richard Herrmann, Aron Goldhirsch, Christoph Hürny

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Psychosocial factors have been described as affecting cellular immune measures in healthy subjects. In patients with early breast cancer we explored bi-directional psycho-immune effects to determine whether subjective burden has an impact on immune measures, and vice versa. Patients (n = 239) operated for early breast cancer and randomized into International Breast Cancer Study Group (IBCSG) adjuvant clinical trials were assessed immediately before the beginning of adjuvant treatment (baseline) and 3 and 6 months thereafter, at the beginning of the corresponding treatment cycle. Cellular immune measures (leukocytes, lymphocytes, lymphocyte subset counts), markers of activation of the cellular immune system (β2-microglobulin, soluble interleukin-2 receptor serum levels), and self-report subjective burden (global indicators of physical well-being, mood, coping effort) were assessed concurrently. The relationship between subjective burden and gradients of immune measures was investigated with regression analyses controlling for adjuvant treatment. There was a pattern of small negative associations between all variables assessing subjective burden before the beginning of adjuvant therapy with the gradients of the markers of activation of the cellular immune system and NK cell counts. In particular, better mood predicted a decline in the course of β2- microglobulin and IL-2r at months 3 and 6. The gradient of β2- microglobulin was associated with mood and coping effort at month 3. However, the effect sizes were very small. In conclusion, in this explorative investigation, there was an indication for subjective burden affecting and being affected by markers of activation of the cellular immune system during the first 3 and 6months of adjuvant therapy. The question of clinical significance remains unanswered. These associations have to be investigated with refined assessment tools and schedules.

Original languageEnglish
Pages (from-to)75-86
Number of pages12
JournalBreast Cancer Research and Treatment
Volume87
Issue number1
DOIs
Publication statusPublished - Sep 2004

Fingerprint

Breast Neoplasms
Immune System
Therapeutics
Interleukin-2 Receptors
Lymphocyte Subsets
Lymphocyte Count
Natural Killer Cells
Self Report
Interleukin-2
Appointments and Schedules
Healthy Volunteers
Leukocytes
Cell Count
Regression Analysis
Clinical Trials
Lymphocytes
Psychology
Serum

Keywords

  • adjuvant treatment
  • breast cancer
  • burden
  • distress
  • psycho-immunology
  • quality of life

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Sabbioni, M. E. E., Bernhard, J., Siegrist, H. P., Schmitz, S. F. H., Gertsch, M. C., Thürlimann, B., ... Hürny, C. (2004). Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy? Breast Cancer Research and Treatment, 87(1), 75-86. https://doi.org/10.1023/B:BREA.0000041584.53863.a7

Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy? / Sabbioni, Marzio E E; Bernhard, Jürg; Siegrist, Hans Peter; Schmitz, Shu Fang Hsu; Gertsch, Monica Castiglione; Thürlimann, Beat; Bonnefoi, Hervé; Perey, Lucien; Herrmann, Richard; Goldhirsch, Aron; Hürny, Christoph.

In: Breast Cancer Research and Treatment, Vol. 87, No. 1, 09.2004, p. 75-86.

Research output: Contribution to journalArticle

Sabbioni, MEE, Bernhard, J, Siegrist, HP, Schmitz, SFH, Gertsch, MC, Thürlimann, B, Bonnefoi, H, Perey, L, Herrmann, R, Goldhirsch, A & Hürny, C 2004, 'Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?', Breast Cancer Research and Treatment, vol. 87, no. 1, pp. 75-86. https://doi.org/10.1023/B:BREA.0000041584.53863.a7
Sabbioni, Marzio E E ; Bernhard, Jürg ; Siegrist, Hans Peter ; Schmitz, Shu Fang Hsu ; Gertsch, Monica Castiglione ; Thürlimann, Beat ; Bonnefoi, Hervé ; Perey, Lucien ; Herrmann, Richard ; Goldhirsch, Aron ; Hürny, Christoph. / Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?. In: Breast Cancer Research and Treatment. 2004 ; Vol. 87, No. 1. pp. 75-86.
@article{855e72b3958d477f9aa98192037e8934,
title = "Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?",
abstract = "Psychosocial factors have been described as affecting cellular immune measures in healthy subjects. In patients with early breast cancer we explored bi-directional psycho-immune effects to determine whether subjective burden has an impact on immune measures, and vice versa. Patients (n = 239) operated for early breast cancer and randomized into International Breast Cancer Study Group (IBCSG) adjuvant clinical trials were assessed immediately before the beginning of adjuvant treatment (baseline) and 3 and 6 months thereafter, at the beginning of the corresponding treatment cycle. Cellular immune measures (leukocytes, lymphocytes, lymphocyte subset counts), markers of activation of the cellular immune system (β2-microglobulin, soluble interleukin-2 receptor serum levels), and self-report subjective burden (global indicators of physical well-being, mood, coping effort) were assessed concurrently. The relationship between subjective burden and gradients of immune measures was investigated with regression analyses controlling for adjuvant treatment. There was a pattern of small negative associations between all variables assessing subjective burden before the beginning of adjuvant therapy with the gradients of the markers of activation of the cellular immune system and NK cell counts. In particular, better mood predicted a decline in the course of β2- microglobulin and IL-2r at months 3 and 6. The gradient of β2- microglobulin was associated with mood and coping effort at month 3. However, the effect sizes were very small. In conclusion, in this explorative investigation, there was an indication for subjective burden affecting and being affected by markers of activation of the cellular immune system during the first 3 and 6months of adjuvant therapy. The question of clinical significance remains unanswered. These associations have to be investigated with refined assessment tools and schedules.",
keywords = "adjuvant treatment, breast cancer, burden, distress, psycho-immunology, quality of life",
author = "Sabbioni, {Marzio E E} and J{\"u}rg Bernhard and Siegrist, {Hans Peter} and Schmitz, {Shu Fang Hsu} and Gertsch, {Monica Castiglione} and Beat Th{\"u}rlimann and Herv{\'e} Bonnefoi and Lucien Perey and Richard Herrmann and Aron Goldhirsch and Christoph H{\"u}rny",
year = "2004",
month = "9",
doi = "10.1023/B:BREA.0000041584.53863.a7",
language = "English",
volume = "87",
pages = "75--86",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "1",

}

TY - JOUR

T1 - Does subjective burden of early breast cancer and its treatment affect immune measures during adjuvant therapy?

AU - Sabbioni, Marzio E E

AU - Bernhard, Jürg

AU - Siegrist, Hans Peter

AU - Schmitz, Shu Fang Hsu

AU - Gertsch, Monica Castiglione

AU - Thürlimann, Beat

AU - Bonnefoi, Hervé

AU - Perey, Lucien

AU - Herrmann, Richard

AU - Goldhirsch, Aron

AU - Hürny, Christoph

PY - 2004/9

Y1 - 2004/9

N2 - Psychosocial factors have been described as affecting cellular immune measures in healthy subjects. In patients with early breast cancer we explored bi-directional psycho-immune effects to determine whether subjective burden has an impact on immune measures, and vice versa. Patients (n = 239) operated for early breast cancer and randomized into International Breast Cancer Study Group (IBCSG) adjuvant clinical trials were assessed immediately before the beginning of adjuvant treatment (baseline) and 3 and 6 months thereafter, at the beginning of the corresponding treatment cycle. Cellular immune measures (leukocytes, lymphocytes, lymphocyte subset counts), markers of activation of the cellular immune system (β2-microglobulin, soluble interleukin-2 receptor serum levels), and self-report subjective burden (global indicators of physical well-being, mood, coping effort) were assessed concurrently. The relationship between subjective burden and gradients of immune measures was investigated with regression analyses controlling for adjuvant treatment. There was a pattern of small negative associations between all variables assessing subjective burden before the beginning of adjuvant therapy with the gradients of the markers of activation of the cellular immune system and NK cell counts. In particular, better mood predicted a decline in the course of β2- microglobulin and IL-2r at months 3 and 6. The gradient of β2- microglobulin was associated with mood and coping effort at month 3. However, the effect sizes were very small. In conclusion, in this explorative investigation, there was an indication for subjective burden affecting and being affected by markers of activation of the cellular immune system during the first 3 and 6months of adjuvant therapy. The question of clinical significance remains unanswered. These associations have to be investigated with refined assessment tools and schedules.

AB - Psychosocial factors have been described as affecting cellular immune measures in healthy subjects. In patients with early breast cancer we explored bi-directional psycho-immune effects to determine whether subjective burden has an impact on immune measures, and vice versa. Patients (n = 239) operated for early breast cancer and randomized into International Breast Cancer Study Group (IBCSG) adjuvant clinical trials were assessed immediately before the beginning of adjuvant treatment (baseline) and 3 and 6 months thereafter, at the beginning of the corresponding treatment cycle. Cellular immune measures (leukocytes, lymphocytes, lymphocyte subset counts), markers of activation of the cellular immune system (β2-microglobulin, soluble interleukin-2 receptor serum levels), and self-report subjective burden (global indicators of physical well-being, mood, coping effort) were assessed concurrently. The relationship between subjective burden and gradients of immune measures was investigated with regression analyses controlling for adjuvant treatment. There was a pattern of small negative associations between all variables assessing subjective burden before the beginning of adjuvant therapy with the gradients of the markers of activation of the cellular immune system and NK cell counts. In particular, better mood predicted a decline in the course of β2- microglobulin and IL-2r at months 3 and 6. The gradient of β2- microglobulin was associated with mood and coping effort at month 3. However, the effect sizes were very small. In conclusion, in this explorative investigation, there was an indication for subjective burden affecting and being affected by markers of activation of the cellular immune system during the first 3 and 6months of adjuvant therapy. The question of clinical significance remains unanswered. These associations have to be investigated with refined assessment tools and schedules.

KW - adjuvant treatment

KW - breast cancer

KW - burden

KW - distress

KW - psycho-immunology

KW - quality of life

UR - http://www.scopus.com/inward/record.url?scp=4544376367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544376367&partnerID=8YFLogxK

U2 - 10.1023/B:BREA.0000041584.53863.a7

DO - 10.1023/B:BREA.0000041584.53863.a7

M3 - Article

C2 - 15377853

AN - SCOPUS:4544376367

VL - 87

SP - 75

EP - 86

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -